Last reviewed · How we verify
Medicis Global Service Corporation — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide | Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide | marketed | ||||
| Product 55394 | Product 55394 | phase 3 | topical retinoid | Dermatology |
Therapeutic area mix
- Dermatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Galderma R&D · 1 shared drug class
- Sol-Gel Technologies, Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Medicis Global Service Corporation:
- Medicis Global Service Corporation pipeline updates — RSS
- Medicis Global Service Corporation pipeline updates — Atom
- Medicis Global Service Corporation pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Medicis Global Service Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medicis-global-service-corporation. Accessed 2026-05-17.